<?xml version="1.0" encoding="UTF-8"?>
<p id="Par56">Opioid substitution therapies significantly reduce the frequency of injection drug use (Kwiatkowski and Booth 
 <xref ref-type="bibr" rid="CR265">2001</xref>; Pettes et al. 
 <xref ref-type="bibr" rid="CR397">2010</xref>), decrease HIV transmission risk (MacArthur et al. 
 <xref ref-type="bibr" rid="CR299">2012</xref>; Platt et al. 
 <xref ref-type="bibr" rid="CR400">2016</xref>), and reduce drug-related mortality (Mathers et al. 
 <xref ref-type="bibr" rid="CR316">2013</xref>) and the risk of opioid overdose (Volkow et al. 
 <xref ref-type="bibr" rid="CR530">2014</xref>). Further, improved ARV outcomes among PWH have been reported with opioid substitution therapies, including the uptake and retention on ARV, medication adherence rates, and viral suppression (Low et al. 
 <xref ref-type="bibr" rid="CR297">2016</xref>; Mukandavire et al. 
 <xref ref-type="bibr" rid="CR347">2017</xref>). The two main medications used for opioid substitution therapy include methadone, a MOR full agonist, and buprenorphine, a MOR partial agonist and partial antagonist of KOR (Noble and Marie 
 <xref ref-type="bibr" rid="CR365">2018</xref>). In comparison to methadone, buprenorphine has been shown to have fewer pharmacodynamic interactions with ARVs and causes less opioid withdrawal symptoms potentially due to its partial agonism on MOR, but also due to its high affinity and long duration of MOR binding (Walsh et al. 
 <xref ref-type="bibr" rid="CR534">1994</xref>; McCance-Katz 
 <xref ref-type="bibr" rid="CR322">2005</xref>; Whelan and Remski 
 <xref ref-type="bibr" rid="CR538">2012</xref>). Further, differential proinflammatory and neurotoxic effects have been noted for various opioid treatments (Boland et al. 
 <xref ref-type="bibr" rid="CR50">2014</xref>; Fitting et al. 
 <xref ref-type="bibr" rid="CR163">2014b</xref>; Carvallo et al. 
 <xref ref-type="bibr" rid="CR76">2015</xref>; Dutta and Roy 
 <xref ref-type="bibr" rid="CR124">2015</xref>). In primary astrocytes, agonist-selective actions at MOR and KOR can be clearly demonstrated (Bohn et al. 
 <xref ref-type="bibr" rid="CR46">2000</xref>; Belcheva et al. 
 <xref ref-type="bibr" rid="CR34">2003</xref>; McLennan et al. 
 <xref ref-type="bibr" rid="CR329">2008</xref>; Hahn et al. 
 <xref ref-type="bibr" rid="CR198">2010</xref>), and we found that morphine, methadone, and buprenorphine differentially increase ROS and [Ca
 <sup>2+</sup>]
 <sub>i</sub> alone or following Tat co-exposure (Fitting et al. 
 <xref ref-type="bibr" rid="CR163">2014b</xref>). Morphine can enhance HIV-1-induced production of cytokines and specifically chemokines (El-Hage et al. 
 <xref ref-type="bibr" rid="CR133">2008a</xref>; Dave 
 <xref ref-type="bibr" rid="CR111">2012</xref>; El-Hage et al. 
 <xref ref-type="bibr" rid="CR138">2014</xref>), while other opioids including methadone, oxycodone, buprenorphine, and DAMGO can decrease inflammatory function and decrease monocyte migration (Boland et al. 
 <xref ref-type="bibr" rid="CR50">2014</xref>; Carvallo et al. 
 <xref ref-type="bibr" rid="CR76">2015</xref>; Jaureguiberry-Bravo et al. 
 <xref ref-type="bibr" rid="CR225">2016</xref>; Chilunda et al. 
 <xref ref-type="bibr" rid="CR92">2019</xref>).
</p>
